In this piece, we will look at the stocks that Jim Cramer recently discussed.
In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer commented on Federal Reserve Governor. Lisa Cook and President Trump’s decision to fire her. The matter is currently in court as the Fed official seeks a stay order against Trump’s action. The action carries ramifications for financial markets, and Cramer believes that the matter will eventually be resolved in the Supreme Court:
“Right and as Steve [Steve Liesman] mentioned, look if the facts say that, that there is, that it’s warranted, that this is actually a substative thing, maybe it can trump what the carveout is. But look I just think it’s going to go to the Supreme Court. And this maybe the big case about all these firings and what you can and can’t do. I know that they’ve relied on a series of cases which have increased the power of the executive over the last few years. And that may cut in favor of Trump.”
Our Methodology
To make our list of the stocks that Jim Cramer talked about, we listed down the stocks he mentioned during CNBC’s Squawk on the Street aired on August 28th.
For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13. Amgen Inc. (NASDAQ:AMGN)
Number of Hedge Fund Holders In Q2 2025: 62
Amgen Inc. (NASDAQ:AMGN) is one of the largest pharmaceutical companies in the world that makes treatments for a variety of ailments such as arthritis, heart problems, and anemia. The shares have gained 10.8% year-to-date on the back of several catalysts, such as positive data about its cancer drug. Cramer’s previous comments about the firm have called it a bargain due to excessive weakness stemming from a weight loss drug trial. This time, he commented on Amgen Inc. (NASDAQ:AMGN)’s coronary artery disease medicine and valuation:
“I take medicine, called Repatha, by the way, which is really good, it’s an Amgen medicine. It lowers cholesterol, and it’s said to be maybe removing plaque from your brain. You want that. But David. It hurts like you wouldn’t believe it, like a banshee. Like a banshee. I mean every Sunday, I’m like aaaaah, now maybe it’s because I’m sensitive. Kind of like your dial up, pssh khwuuum. . .and I wish it were [available in oral form] because boy it’s an amazing medication. I think I wish for Amgen, get than thing in a pill form, everybody in the world would be taking it. Stock’s at 285, sells at 13 times earnings, that’s crazy.”
Here is what Cramer said about Amgen Inc. (NASDAQ:AMGN)’s weight loss drug:
“Unlike Mounjaro or Ozempic, which needed to be injected once a week, Amgen’s MariTide is one shot per month. I prefer monthly over weekly when it comes to injections any day… So what did we learn when Amgen presented on Monday afternoon? First, the market didn’t like it. The stock sold off. Hard response… There… [was] some genuinely new information too. I’m talking about the Phase 1 trial, data from the separate trial, studying much lower starting doses of MariTide with different escalation schedules, far less vomiting at the low doses…
This is really important because it seems to go down easier when patients start at a lower dose and then ratchet up gradually. So what exactly does this mean for Amgen, the stock? Again, Wall Street was not impressed. When Amgen published this data on Monday afternoon, the stock dropped an incredible 15 points in just a few minutes, finishing the day down almost 6%. But over the past two days, the stock’s recovered a big chunk of the ground that was lost, so maybe there’s something good here…
My bigger concern, we may not see MariTide get FDA approval and make it to the market until late 2027 at best… Amgen’s very confident that their Phase 3 trial will be successful by the time 2027 comes along. Millions of people will probably be taking that Lily weight loss pill. That said, the stock… sold off to the point where I would not bet against it…
I don’t think that new MariTide data is bad enough to justify this decline. And now you’re getting a bargain. That’s right, Amgen’s at a bargain, basement price of 13 times earnings…. And while Lilly’s a great stock that certainly deserves a premium… I think Amgen’s gotten too cheap by comparison.
This is still a big biotech company with mid-single-digit earnings growth expected this year, not to mention potential upside for this GLP-1 drug down the road. But here’s the bottom line: We got plenty of data from this American Diabetes Association conference that ended earlier this week, and I think Amgen’s trial results were misunderstood. The stock did not deserve to get hit this hard. Lily’s still my favorite way to play the GLP-1 story. But if you’re looking for a bargain, you could do a lot worse than Amgen.”
12. Abbott Laboratories (NYSE:ABT)
Number of Hedge Fund Holders In Q2 2025: 69
Abbott Laboratories (NYSE:ABT)’s shares have gained 16.7% year-to-date despite suffering from a major dip in July. The shares sank by 8.5% after the firm’s second-quarter earnings failed to satiate growth-hungry investors. While Abbott Laboratories (NYSE:ABT) beat analyst estimates for earnings and revenue, its decision to keep guidance unchanged was just too much for investors to bear. In his previous comments about the firm, Cramer shared that he was among those who were looking for a guidance raise. This time, he shared what might be a potential catalyst for Abbott Laboratories (NYSE:ABT):
“You know what, my colleague Jeff Marks said this could be good for Abbott. The Binax. Cause it looks like you know if you’re not going to give the COVID vaccine then a lot of people maybe you need the test. So maybe you buy Abbott off the Binax. I don’t know. I think Abbott’s much more of a. . .”
Here’s what Cramer said about Abbott Laboratories (NYSE:ABT) after its earnings:
“Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company that we’ve long owned for the Charitable Trust… I’d say two decades. When Abbott Labs reported this morning, the… results were perfectly solid. Management tightened their full-year earnings guidance rather than raising it while also taking down their organic sales growth forecast and their operating margin outlook.
A lot of investors, including me, have been hoping they’d raise these numbers, so the stock got clobbered down more than $11 or 8.5%. I thought it might’ve been down $15. That’s what I predicted. It didn’t get that low. As I’ve chronicled many times, this is a stock where we’ve really had to battle over the past several quarters. We’ve kept our faith for the Charitable Trust during some nasty litigation last year. The stock bounced back from that.”